APELLIS PHARMACEUTICALS INC (APLS)       66.18  +1.2 (+1.85%)

66.18  +1.2 (+1.85%)

US03753U1060 - Common Stock - After market: 66.18 0 (0%)

Buy % Consensus

83
Analysts have set a mean price target of 87.38. This target is 32.03% above the current price.
APLS was analyzed by 23 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about APLS.
In the previous month the buy percentage consensus was at a similar level.
APLS was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 66.1851.5183.6487.38145.95 - -22.17% 26.38% 32.03% 120.53%

Up and Down Grades

Date Firm Action Rating
2023-02-23 HC Wainwright & Co. Reiterate Buy
2023-02-22 Needham Maintains Buy
2023-02-22 Raymond James Maintains Strong Buy
2023-02-21 Needham Reiterate Buy
2023-02-21 Stifel Maintains Buy
2023-02-21 Baird Maintains Outperform
2023-02-21 Citigroup Maintains Buy
2023-02-21 HC Wainwright & Co. Reiterate Buy
2023-01-03 Wells Fargo Downgrade Overweight -> Equal-Weight
2022-11-15 JP Morgan Maintains Overweight
2022-11-10 Jefferies Downgrade Buy -> Hold
2022-11-08 Credit Suisse Maintains Neutral
2022-10-18 Raymond James Maintains Strong Buy
2022-09-12 Wedbush Maintains Neutral
2022-09-08 Stifel Maintains Buy
2022-08-18 Oppenheimer Maintains Outperform
2022-08-09 Raymond James Maintains Strong Buy
2022-08-09 Goldman Sachs Maintains Buy
2022-08-09 Credit Suisse Maintains Neutral
2022-07-20 Citigroup Maintains Buy
2022-07-19 HC Wainwright & Co. Initiate Buy
2022-05-24 Goldman Sachs Maintains Buy
2022-05-05 Raymond James Maintains Strong Buy
2022-05-05 Credit Suisse Maintains Neutral
2022-04-14 Roth Capital Downgrade Neutral -> Sell
2022-03-07 Goldman Sachs Maintains Buy
2022-03-01 Raymond James Maintains Strong Buy
2022-01-11 Raymond James Maintains Strong Buy
2021-12-08 Wells Fargo Initiate Overweight
2021-11-29 Roth Capital Downgrade Buy -> Neutral

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA